[HTML][HTML] Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD

R Jin, JA Welsh, NA Le, J Holzberg, P Sharma… - Nutrients, 2014 - mdpi.com
R Jin, JA Welsh, NA Le, J Holzberg, P Sharma, DR Martin, MB Vos
Nutrients, 2014mdpi.com
Nonalcoholic fatty liver disease (NAFLD) is now thought to be the most common liver
disease worldwide. Cardiovascular complications are a leading cause of mortality in
NAFLD. Fructose, a common nutrient in the westernized diet, has been reported to be
associated with increased cardiovascular risk, but its impact on adolescents with NAFLD is
not well understood. We designed a 4-week randomized, controlled, double-blinded
beverage intervention study. Twenty-four overweight Hispanic-American adolescents who …
Nonalcoholic fatty liver disease (NAFLD) is now thought to be the most common liver disease worldwide. Cardiovascular complications are a leading cause of mortality in NAFLD. Fructose, a common nutrient in the westernized diet, has been reported to be associated with increased cardiovascular risk, but its impact on adolescents with NAFLD is not well understood. We designed a 4-week randomized, controlled, double-blinded beverage intervention study. Twenty-four overweight Hispanic-American adolescents who had hepatic fat >8% on imaging and who were regular consumers of sweet beverages were enrolled and randomized to calorie-matched study-provided fructose only or glucose only beverages. After 4 weeks, there was no significant change in hepatic fat or body weight in either group. In the glucose beverage group there was significantly improved adipose insulin sensitivity, high sensitivity C-reactive protein (hs-CRP), and low-density lipoprotein (LDL) oxidation. These findings demonstrate that reduction of fructose improves several important factors related to cardiovascular disease despite a lack of measurable improvement in hepatic steatosis. Reducing dietary fructose may be an effective intervention to blunt atherosclerosis progression among NAFLD patients and should be evaluated in longer term clinical trials.
MDPI